Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Publication
, Journal Article
Crews, KR; Gaedigk, A; Dunnenberger, HM; Klein, TE; Shen, DD; Callaghan, JT; Kharasch, ED; Skaar, TC ...
Published in: Clin Pharmacol Ther
February 2012
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.
Duke Scholars
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
February 2012
Volume
91
Issue
2
Start / End Page
321 / 326
Location
United States
Related Subject Headings
- Polymorphism, Genetic
- Phenotype
- Pharmacology & Pharmacy
- Pharmacogenetics
- Humans
- Genetic Testing
- Drug Dosage Calculations
- Cytochrome P-450 CYP2D6
- Codeine
- Analgesics, Opioid
Citation
APA
Chicago
ICMJE
MLA
NLM
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., … Clinical Pharmacogenetics Implementation Consortium. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther, 91(2), 321–326. https://doi.org/10.1038/clpt.2011.287
Crews, K. R., A. Gaedigk, H. M. Dunnenberger, T. E. Klein, D. D. Shen, J. T. Callaghan, E. D. Kharasch, T. C. Skaar, and Clinical Pharmacogenetics Implementation Consortium. “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.” Clin Pharmacol Ther 91, no. 2 (February 2012): 321–26. https://doi.org/10.1038/clpt.2011.287.
Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb;91(2):321–6.
Crews, K. R., et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.” Clin Pharmacol Ther, vol. 91, no. 2, Feb. 2012, pp. 321–26. Pubmed, doi:10.1038/clpt.2011.287.
Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb;91(2):321–326.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
February 2012
Volume
91
Issue
2
Start / End Page
321 / 326
Location
United States
Related Subject Headings
- Polymorphism, Genetic
- Phenotype
- Pharmacology & Pharmacy
- Pharmacogenetics
- Humans
- Genetic Testing
- Drug Dosage Calculations
- Cytochrome P-450 CYP2D6
- Codeine
- Analgesics, Opioid